<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d489" origId="Aprepitant"><sentence id="DrugDDI.d489.s0" origId="s0" text="Aprepitant is a substrate, a moderate inhibitor, and an inducer of CYP3A4."><entity id="DrugDDI.d489.s0.e0" origId="s0.p0" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s0.e1" origId="s0.p6" charOffset="67-73" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s0.p0" e1="DrugDDI.d489.s0.e0" e2="DrugDDI.d489.s0.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s1" origId="s1" text="Aprepitant is also an inducer of CYP2C9."><entity id="DrugDDI.d489.s1.e0" origId="s1.p7" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s1.e1" origId="s1.p10" charOffset="33-39" type="drug" text="CYP2C9"/><pair id="DrugDDI.d489.s1.p0" e1="DrugDDI.d489.s1.e0" e2="DrugDDI.d489.s1.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s2" origId="s2" text="Effect of aprepitant on the pharmacokinetics of other agents"><entity id="DrugDDI.d489.s2.e0" origId="s2.p12" charOffset="10-20" type="drug" text="aprepitant"/></sentence><sentence id="DrugDDI.d489.s3" origId="s3" text="As a moderate inhibitor of CYP3A4, aprepitant can increase plasma concentrations of coadministered medicinal products that are metabolized through CYP3A4."><entity id="DrugDDI.d489.s3.e0" origId="s3.p16" charOffset="27-33" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s3.e1" origId="s3.p17" charOffset="35-45" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s3.e2" origId="s3.p21" charOffset="99-116" type="drug" text="medicinal product"/><entity id="DrugDDI.d489.s3.e3" origId="s3.p25" charOffset="147-153" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s3.p0" e1="DrugDDI.d489.s3.e0" e2="DrugDDI.d489.s3.e1" interaction="false"/><pair id="DrugDDI.d489.s3.p1" e1="DrugDDI.d489.s3.e0" e2="DrugDDI.d489.s3.e2" interaction="false"/><pair id="DrugDDI.d489.s3.p2" e1="DrugDDI.d489.s3.e0" e2="DrugDDI.d489.s3.e3" interaction="false"/><pair id="DrugDDI.d489.s3.p3" e1="DrugDDI.d489.s3.e1" e2="DrugDDI.d489.s3.e2" interaction="true"/><pair id="DrugDDI.d489.s3.p4" e1="DrugDDI.d489.s3.e1" e2="DrugDDI.d489.s3.e3" interaction="false"/><pair id="DrugDDI.d489.s3.p5" e1="DrugDDI.d489.s3.e2" e2="DrugDDI.d489.s3.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s4" origId="s4" text="Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9."><entity id="DrugDDI.d489.s4.e0" origId="s4.p26" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s4.e1" origId="s4.p35" charOffset="59-67" type="drug" text="warfarin"/><entity id="DrugDDI.d489.s4.e2" origId="s4.p37" charOffset="72-83" type="drug" text="tolbutamide"/><entity id="DrugDDI.d489.s4.e3" origId="s4.p41" charOffset="115-121" type="drug" text="CYP2C9"/><pair id="DrugDDI.d489.s4.p0" e1="DrugDDI.d489.s4.e0" e2="DrugDDI.d489.s4.e1" interaction="true"/><pair id="DrugDDI.d489.s4.p1" e1="DrugDDI.d489.s4.e0" e2="DrugDDI.d489.s4.e2" interaction="false"/><pair id="DrugDDI.d489.s4.p2" e1="DrugDDI.d489.s4.e0" e2="DrugDDI.d489.s4.e3" interaction="false"/><pair id="DrugDDI.d489.s4.p3" e1="DrugDDI.d489.s4.e1" e2="DrugDDI.d489.s4.e2" interaction="false"/><pair id="DrugDDI.d489.s4.p4" e1="DrugDDI.d489.s4.e1" e2="DrugDDI.d489.s4.e3" interaction="false"/><pair id="DrugDDI.d489.s4.p5" e1="DrugDDI.d489.s4.e2" e2="DrugDDI.d489.s4.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s5" origId="s5" text="Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs."><entity id="DrugDDI.d489.s5.e0" origId="s5.p43" charOffset="20-30" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s5.e1" origId="s5.p44" charOffset="42-47" type="drug" text="drugs"/><entity id="DrugDDI.d489.s5.e2" origId="s5.p46" charOffset="57-62" type="drug" text="drugs"/><entity id="DrugDDI.d489.s5.e3" origId="s5.p53" charOffset="99-105" type="drug" text="CYP2C9"/><entity id="DrugDDI.d489.s5.e4" origId="s5.p54" charOffset="115-124" type="drug" text="phenytoin"/><entity id="DrugDDI.d489.s5.e5" origId="s5.p58" charOffset="177-182" type="drug" text="drugs"/><pair id="DrugDDI.d489.s5.p0" e1="DrugDDI.d489.s5.e0" e2="DrugDDI.d489.s5.e1" interaction="true"/><pair id="DrugDDI.d489.s5.p1" e1="DrugDDI.d489.s5.e0" e2="DrugDDI.d489.s5.e2" interaction="false"/><pair id="DrugDDI.d489.s5.p2" e1="DrugDDI.d489.s5.e0" e2="DrugDDI.d489.s5.e3" interaction="false"/><pair id="DrugDDI.d489.s5.p3" e1="DrugDDI.d489.s5.e0" e2="DrugDDI.d489.s5.e4" interaction="true"/><pair id="DrugDDI.d489.s5.p4" e1="DrugDDI.d489.s5.e0" e2="DrugDDI.d489.s5.e5" interaction="false"/><pair id="DrugDDI.d489.s5.p5" e1="DrugDDI.d489.s5.e1" e2="DrugDDI.d489.s5.e2" interaction="false"/><pair id="DrugDDI.d489.s5.p6" e1="DrugDDI.d489.s5.e1" e2="DrugDDI.d489.s5.e3" interaction="false"/><pair id="DrugDDI.d489.s5.p7" e1="DrugDDI.d489.s5.e1" e2="DrugDDI.d489.s5.e4" interaction="false"/><pair id="DrugDDI.d489.s5.p8" e1="DrugDDI.d489.s5.e1" e2="DrugDDI.d489.s5.e5" interaction="false"/><pair id="DrugDDI.d489.s5.p9" e1="DrugDDI.d489.s5.e2" e2="DrugDDI.d489.s5.e3" interaction="false"/><pair id="DrugDDI.d489.s5.p10" e1="DrugDDI.d489.s5.e2" e2="DrugDDI.d489.s5.e4" interaction="false"/><pair id="DrugDDI.d489.s5.p11" e1="DrugDDI.d489.s5.e2" e2="DrugDDI.d489.s5.e5" interaction="false"/><pair id="DrugDDI.d489.s5.p12" e1="DrugDDI.d489.s5.e3" e2="DrugDDI.d489.s5.e4" interaction="false"/><pair id="DrugDDI.d489.s5.p13" e1="DrugDDI.d489.s5.e3" e2="DrugDDI.d489.s5.e5" interaction="false"/><pair id="DrugDDI.d489.s5.p14" e1="DrugDDI.d489.s5.e4" e2="DrugDDI.d489.s5.e5" interaction="false"/></sentence><sentence id="DrugDDI.d489.s6" origId="s6" text="Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with digoxin in a clinical drug interaction study."><entity id="DrugDDI.d489.s6.e0" origId="s6.p59" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s6.e1" origId="s6.p63" charOffset="40-45" type="drug" text="drugs"/><entity id="DrugDDI.d489.s6.e2" origId="s6.p67" charOffset="76-88" type="drug" text="glycoprotein"/><entity id="DrugDDI.d489.s6.e3" origId="s6.p72" charOffset="148-158" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s6.e4" origId="s6.p73" charOffset="164-171" type="drug" text="digoxin"/><pair id="DrugDDI.d489.s6.p0" e1="DrugDDI.d489.s6.e0" e2="DrugDDI.d489.s6.e1" interaction="false"/><pair id="DrugDDI.d489.s6.p1" e1="DrugDDI.d489.s6.e0" e2="DrugDDI.d489.s6.e2" interaction="false"/><pair id="DrugDDI.d489.s6.p2" e1="DrugDDI.d489.s6.e0" e2="DrugDDI.d489.s6.e3" interaction="false"/><pair id="DrugDDI.d489.s6.p3" e1="DrugDDI.d489.s6.e0" e2="DrugDDI.d489.s6.e4" interaction="false"/><pair id="DrugDDI.d489.s6.p4" e1="DrugDDI.d489.s6.e1" e2="DrugDDI.d489.s6.e2" interaction="false"/><pair id="DrugDDI.d489.s6.p5" e1="DrugDDI.d489.s6.e1" e2="DrugDDI.d489.s6.e3" interaction="false"/><pair id="DrugDDI.d489.s6.p6" e1="DrugDDI.d489.s6.e1" e2="DrugDDI.d489.s6.e4" interaction="false"/><pair id="DrugDDI.d489.s6.p7" e1="DrugDDI.d489.s6.e2" e2="DrugDDI.d489.s6.e3" interaction="false"/><pair id="DrugDDI.d489.s6.p8" e1="DrugDDI.d489.s6.e2" e2="DrugDDI.d489.s6.e4" interaction="false"/><pair id="DrugDDI.d489.s6.p9" e1="DrugDDI.d489.s6.e3" e2="DrugDDI.d489.s6.e4" interaction="false"/></sentence><sentence id="DrugDDI.d489.s7" origId="s7" text="5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron."><entity id="DrugDDI.d489.s7.e0" origId="s7.p78" charOffset="57-67" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s7.e1" origId="s7.p84" charOffset="137-148" type="drug" text="ondansetron"/><entity id="DrugDDI.d489.s7.e2" origId="s7.p86" charOffset="152-163" type="drug" text="granisetron"/><pair id="DrugDDI.d489.s7.p0" e1="DrugDDI.d489.s7.e0" e2="DrugDDI.d489.s7.e1" interaction="false"/><pair id="DrugDDI.d489.s7.p1" e1="DrugDDI.d489.s7.e0" e2="DrugDDI.d489.s7.e2" interaction="false"/><pair id="DrugDDI.d489.s7.p2" e1="DrugDDI.d489.s7.e1" e2="DrugDDI.d489.s7.e2" interaction="false"/></sentence><sentence id="DrugDDI.d489.s8" origId="s8" text="No clinical or drug interaction study was conducted with dolasetron."><entity id="DrugDDI.d489.s8.e0" origId="s8.p92" charOffset="57-67" type="drug" text="dolasetron"/></sentence><sentence id="DrugDDI.d489.s9" origId="s9" text="Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5."><entity id="DrugDDI.d489.s9.e0" origId="s9.p93" charOffset="0-15" type="drug" text="Corticosteroids"/><entity id="DrugDDI.d489.s9.e1" origId="s9.p95" charOffset="17-30" type="drug" text="Dexamethasone"/><entity id="DrugDDI.d489.s9.e2" origId="s9.p97" charOffset="32-42" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s9.e3" origId="s9.p102" charOffset="82-95" type="drug" text="dexamethasone"/><entity id="DrugDDI.d489.s9.e4" origId="s9.p108" charOffset="141-151" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s9.e5" origId="s9.p113" charOffset="181-194" type="drug" text="dexamethasone"/><entity id="DrugDDI.d489.s9.e6" origId="s9.p121" charOffset="267-280" type="drug" text="dexamethasone"/><entity id="DrugDDI.d489.s9.e7" origId="s9.p122" charOffset="284-290" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s9.p0" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e1" interaction="false"/><pair id="DrugDDI.d489.s9.p1" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e2" interaction="false"/><pair id="DrugDDI.d489.s9.p2" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e3" interaction="false"/><pair id="DrugDDI.d489.s9.p3" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e4" interaction="false"/><pair id="DrugDDI.d489.s9.p4" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e5" interaction="false"/><pair id="DrugDDI.d489.s9.p5" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p6" e1="DrugDDI.d489.s9.e0" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p7" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e2" interaction="false"/><pair id="DrugDDI.d489.s9.p8" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e3" interaction="false"/><pair id="DrugDDI.d489.s9.p9" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e4" interaction="false"/><pair id="DrugDDI.d489.s9.p10" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e5" interaction="false"/><pair id="DrugDDI.d489.s9.p11" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p12" e1="DrugDDI.d489.s9.e1" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p13" e1="DrugDDI.d489.s9.e2" e2="DrugDDI.d489.s9.e3" interaction="true"/><pair id="DrugDDI.d489.s9.p14" e1="DrugDDI.d489.s9.e2" e2="DrugDDI.d489.s9.e4" interaction="false"/><pair id="DrugDDI.d489.s9.p15" e1="DrugDDI.d489.s9.e2" e2="DrugDDI.d489.s9.e5" interaction="false"/><pair id="DrugDDI.d489.s9.p16" e1="DrugDDI.d489.s9.e2" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p17" e1="DrugDDI.d489.s9.e2" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p18" e1="DrugDDI.d489.s9.e3" e2="DrugDDI.d489.s9.e4" interaction="false"/><pair id="DrugDDI.d489.s9.p19" e1="DrugDDI.d489.s9.e3" e2="DrugDDI.d489.s9.e5" interaction="false"/><pair id="DrugDDI.d489.s9.p20" e1="DrugDDI.d489.s9.e3" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p21" e1="DrugDDI.d489.s9.e3" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p22" e1="DrugDDI.d489.s9.e4" e2="DrugDDI.d489.s9.e5" interaction="false"/><pair id="DrugDDI.d489.s9.p23" e1="DrugDDI.d489.s9.e4" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p24" e1="DrugDDI.d489.s9.e4" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p25" e1="DrugDDI.d489.s9.e5" e2="DrugDDI.d489.s9.e6" interaction="false"/><pair id="DrugDDI.d489.s9.p26" e1="DrugDDI.d489.s9.e5" e2="DrugDDI.d489.s9.e7" interaction="false"/><pair id="DrugDDI.d489.s9.p27" e1="DrugDDI.d489.s9.e6" e2="DrugDDI.d489.s9.e7" interaction="false"/></sentence><sentence id="DrugDDI.d489.s10" origId="s10" text="The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant."><entity id="DrugDDI.d489.s10.e0" origId="s10.p127" charOffset="4-22" type="drug" text="oral dexamethasone"/><entity id="DrugDDI.d489.s10.e1" origId="s10.p134" charOffset="93-103" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s10.e2" origId="s10.p138" charOffset="129-142" type="drug" text="dexamethasone"/><entity id="DrugDDI.d489.s10.e3" origId="s10.p144" charOffset="194-204" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s10.p0" e1="DrugDDI.d489.s10.e0" e2="DrugDDI.d489.s10.e1" interaction="true"/><pair id="DrugDDI.d489.s10.p1" e1="DrugDDI.d489.s10.e0" e2="DrugDDI.d489.s10.e2" interaction="false"/><pair id="DrugDDI.d489.s10.p2" e1="DrugDDI.d489.s10.e0" e2="DrugDDI.d489.s10.e3" interaction="false"/><pair id="DrugDDI.d489.s10.p3" e1="DrugDDI.d489.s10.e1" e2="DrugDDI.d489.s10.e2" interaction="false"/><pair id="DrugDDI.d489.s10.p4" e1="DrugDDI.d489.s10.e1" e2="DrugDDI.d489.s10.e3" interaction="false"/><pair id="DrugDDI.d489.s10.p5" e1="DrugDDI.d489.s10.e2" e2="DrugDDI.d489.s10.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s11" origId="s11" text="The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone."><entity id="DrugDDI.d489.s11.e0" origId="s11.p146" charOffset="18-31" type="drug" text="dexamethasone"/><entity id="DrugDDI.d489.s11.e1" origId="s11.p149" charOffset="70-80" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s11.e2" origId="s11.p153" charOffset="134-147" type="drug" text="dexamethasone"/><pair id="DrugDDI.d489.s11.p0" e1="DrugDDI.d489.s11.e0" e2="DrugDDI.d489.s11.e1" interaction="true"/><pair id="DrugDDI.d489.s11.p1" e1="DrugDDI.d489.s11.e0" e2="DrugDDI.d489.s11.e2" interaction="false"/><pair id="DrugDDI.d489.s11.p2" e1="DrugDDI.d489.s11.e1" e2="DrugDDI.d489.s11.e2" interaction="false"/></sentence><sentence id="DrugDDI.d489.s12" origId="s12" text="Methylprednisolone"><entity id="DrugDDI.d489.s12.e0" origId="s12.p154" charOffset="0-18" type="drug" text="Methylprednisolone"/></sentence><sentence id="DrugDDI.d489.s13" origId="s13" text="Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3."><entity id="DrugDDI.d489.s13.e0" origId="s13.p155" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s13.e1" origId="s13.p169" charOffset="107-125" type="drug" text="methylprednisolone"/><entity id="DrugDDI.d489.s13.e2" origId="s13.p170" charOffset="129-135" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s13.e3" origId="s13.p177" charOffset="200-218" type="drug" text="methylprednisolone"/><pair id="DrugDDI.d489.s13.p0" e1="DrugDDI.d489.s13.e0" e2="DrugDDI.d489.s13.e1" interaction="true"/><pair id="DrugDDI.d489.s13.p1" e1="DrugDDI.d489.s13.e0" e2="DrugDDI.d489.s13.e2" interaction="false"/><pair id="DrugDDI.d489.s13.p2" e1="DrugDDI.d489.s13.e0" e2="DrugDDI.d489.s13.e3" interaction="false"/><pair id="DrugDDI.d489.s13.p3" e1="DrugDDI.d489.s13.e1" e2="DrugDDI.d489.s13.e2" interaction="false"/><pair id="DrugDDI.d489.s13.p4" e1="DrugDDI.d489.s13.e1" e2="DrugDDI.d489.s13.e3" interaction="false"/><pair id="DrugDDI.d489.s13.p5" e1="DrugDDI.d489.s13.e2" e2="DrugDDI.d489.s13.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s14" origId="s14" text="The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant."><entity id="DrugDDI.d489.s14.e0" origId="s14.p189" charOffset="7-25" type="drug" text="methylprednisolone"/><entity id="DrugDDI.d489.s14.e1" origId="s14.p195" charOffset="79-102" type="drug" text="oral methylprednisolone"/><entity id="DrugDDI.d489.s14.e2" origId="s14.p202" charOffset="172-182" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s14.e3" origId="s14.p206" charOffset="207-225" type="drug" text="methylprednisolone"/><entity id="DrugDDI.d489.s14.e4" origId="s14.p212" charOffset="277-287" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s14.p0" e1="DrugDDI.d489.s14.e0" e2="DrugDDI.d489.s14.e1" interaction="false"/><pair id="DrugDDI.d489.s14.p1" e1="DrugDDI.d489.s14.e0" e2="DrugDDI.d489.s14.e2" interaction="true"/><pair id="DrugDDI.d489.s14.p2" e1="DrugDDI.d489.s14.e0" e2="DrugDDI.d489.s14.e3" interaction="false"/><pair id="DrugDDI.d489.s14.p3" e1="DrugDDI.d489.s14.e0" e2="DrugDDI.d489.s14.e4" interaction="false"/><pair id="DrugDDI.d489.s14.p4" e1="DrugDDI.d489.s14.e1" e2="DrugDDI.d489.s14.e2" interaction="false"/><pair id="DrugDDI.d489.s14.p5" e1="DrugDDI.d489.s14.e1" e2="DrugDDI.d489.s14.e3" interaction="false"/><pair id="DrugDDI.d489.s14.p6" e1="DrugDDI.d489.s14.e1" e2="DrugDDI.d489.s14.e4" interaction="false"/><pair id="DrugDDI.d489.s14.p7" e1="DrugDDI.d489.s14.e2" e2="DrugDDI.d489.s14.e3" interaction="false"/><pair id="DrugDDI.d489.s14.p8" e1="DrugDDI.d489.s14.e2" e2="DrugDDI.d489.s14.e4" interaction="false"/><pair id="DrugDDI.d489.s14.p9" e1="DrugDDI.d489.s14.e3" e2="DrugDDI.d489.s14.e4" interaction="false"/></sentence><sentence id="DrugDDI.d489.s15" origId="s15" text="Warfarin: A single 125-mg dose of Aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic warfarin therapy."><entity id="DrugDDI.d489.s15.e0" origId="s15.p213" charOffset="0-8" type="drug" text="Warfarin"/><entity id="DrugDDI.d489.s15.e1" origId="s15.p216" charOffset="34-44" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s15.e2" origId="s15.p230" charOffset="152-160" type="drug" text="warfarin"/><pair id="DrugDDI.d489.s15.p0" e1="DrugDDI.d489.s15.e0" e2="DrugDDI.d489.s15.e1" interaction="false"/><pair id="DrugDDI.d489.s15.p1" e1="DrugDDI.d489.s15.e0" e2="DrugDDI.d489.s15.e2" interaction="false"/><pair id="DrugDDI.d489.s15.p2" e1="DrugDDI.d489.s15.e1" e2="DrugDDI.d489.s15.e2" interaction="true"/></sentence><sentence id="DrugDDI.d489.s16" origId="s16" text="Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant."><entity id="DrugDDI.d489.s16.e0" origId="s16.p235" charOffset="32-42" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s16.e1" origId="s16.p242" charOffset="77-85" type="drug" text="warfarin"/><entity id="DrugDDI.d489.s16.e2" origId="s16.p250" charOffset="139-147" type="drug" text="warfarin"/><entity id="DrugDDI.d489.s16.e3" origId="s16.p252" charOffset="151-157" type="drug" text="CYP2C9"/><entity id="DrugDDI.d489.s16.e4" origId="s16.p267" charOffset="335-345" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s16.p0" e1="DrugDDI.d489.s16.e0" e2="DrugDDI.d489.s16.e1" interaction="false"/><pair id="DrugDDI.d489.s16.p1" e1="DrugDDI.d489.s16.e0" e2="DrugDDI.d489.s16.e2" interaction="false"/><pair id="DrugDDI.d489.s16.p2" e1="DrugDDI.d489.s16.e0" e2="DrugDDI.d489.s16.e3" interaction="false"/><pair id="DrugDDI.d489.s16.p3" e1="DrugDDI.d489.s16.e0" e2="DrugDDI.d489.s16.e4" interaction="false"/><pair id="DrugDDI.d489.s16.p4" e1="DrugDDI.d489.s16.e1" e2="DrugDDI.d489.s16.e2" interaction="false"/><pair id="DrugDDI.d489.s16.p5" e1="DrugDDI.d489.s16.e1" e2="DrugDDI.d489.s16.e3" interaction="false"/><pair id="DrugDDI.d489.s16.p6" e1="DrugDDI.d489.s16.e1" e2="DrugDDI.d489.s16.e4" interaction="false"/><pair id="DrugDDI.d489.s16.p7" e1="DrugDDI.d489.s16.e2" e2="DrugDDI.d489.s16.e3" interaction="false"/><pair id="DrugDDI.d489.s16.p8" e1="DrugDDI.d489.s16.e2" e2="DrugDDI.d489.s16.e4" interaction="false"/><pair id="DrugDDI.d489.s16.p9" e1="DrugDDI.d489.s16.e3" e2="DrugDDI.d489.s16.e4" interaction="false"/></sentence><sentence id="DrugDDI.d489.s17" origId="s17" text="In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle."><entity id="DrugDDI.d489.s17.e0" origId="s17.p269" charOffset="23-31" type="drug" text="warfarin"/><entity id="DrugDDI.d489.s17.e1" origId="s17.p285" charOffset="193-203" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s17.p0" e1="DrugDDI.d489.s17.e0" e2="DrugDDI.d489.s17.e1" interaction="false"/></sentence><sentence id="DrugDDI.d489.s18" origId="s18" text="Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15."><entity id="DrugDDI.d489.s18.e0" origId="s18.p287" charOffset="0-11" type="drug" text="Tolbutamide"/><entity id="DrugDDI.d489.s18.e1" origId="s18.p289" charOffset="13-23" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s18.e2" origId="s18.p302" charOffset="107-118" type="drug" text="tolbutamide"/><entity id="DrugDDI.d489.s18.e3" origId="s18.p304" charOffset="122-128" type="drug" text="CYP2C9"/><entity id="DrugDDI.d489.s18.e4" origId="s18.p315" charOffset="212-230" type="drug" text="tolbutamide 500 mg"/><entity id="DrugDDI.d489.s18.e5" origId="s18.p322" charOffset="308-318" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s18.p0" e1="DrugDDI.d489.s18.e0" e2="DrugDDI.d489.s18.e1" interaction="false"/><pair id="DrugDDI.d489.s18.p1" e1="DrugDDI.d489.s18.e0" e2="DrugDDI.d489.s18.e2" interaction="false"/><pair id="DrugDDI.d489.s18.p2" e1="DrugDDI.d489.s18.e0" e2="DrugDDI.d489.s18.e3" interaction="false"/><pair id="DrugDDI.d489.s18.p3" e1="DrugDDI.d489.s18.e0" e2="DrugDDI.d489.s18.e4" interaction="false"/><pair id="DrugDDI.d489.s18.p4" e1="DrugDDI.d489.s18.e0" e2="DrugDDI.d489.s18.e5" interaction="false"/><pair id="DrugDDI.d489.s18.p5" e1="DrugDDI.d489.s18.e1" e2="DrugDDI.d489.s18.e2" interaction="true"/><pair id="DrugDDI.d489.s18.p6" e1="DrugDDI.d489.s18.e1" e2="DrugDDI.d489.s18.e3" interaction="false"/><pair id="DrugDDI.d489.s18.p7" e1="DrugDDI.d489.s18.e1" e2="DrugDDI.d489.s18.e4" interaction="false"/><pair id="DrugDDI.d489.s18.p8" e1="DrugDDI.d489.s18.e1" e2="DrugDDI.d489.s18.e5" interaction="false"/><pair id="DrugDDI.d489.s18.p9" e1="DrugDDI.d489.s18.e2" e2="DrugDDI.d489.s18.e3" interaction="false"/><pair id="DrugDDI.d489.s18.p10" e1="DrugDDI.d489.s18.e2" e2="DrugDDI.d489.s18.e4" interaction="false"/><pair id="DrugDDI.d489.s18.p11" e1="DrugDDI.d489.s18.e2" e2="DrugDDI.d489.s18.e5" interaction="false"/><pair id="DrugDDI.d489.s18.p12" e1="DrugDDI.d489.s18.e3" e2="DrugDDI.d489.s18.e4" interaction="false"/><pair id="DrugDDI.d489.s18.p13" e1="DrugDDI.d489.s18.e3" e2="DrugDDI.d489.s18.e5" interaction="false"/><pair id="DrugDDI.d489.s18.p14" e1="DrugDDI.d489.s18.e4" e2="DrugDDI.d489.s18.e5" interaction="false"/></sentence><sentence id="DrugDDI.d489.s19" origId="s19" text="Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;"><entity id="DrugDDI.d489.s19.e0" origId="s19.p327" charOffset="0-19" type="drug" text="oral contraceptives"/><entity id="DrugDDI.d489.s19.e1" origId="s19.p329" charOffset="21-31" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s19.e2" origId="s19.p335" charOffset="95-113" type="drug" text="oral contraceptive"/><entity id="DrugDDI.d489.s19.e3" origId="s19.p338" charOffset="135-152" type="drug" text="ethinyl estradiol"/><entity id="DrugDDI.d489.s19.e4" origId="s19.p341" charOffset="165-178" type="drug" text="norethindrone"/><entity id="DrugDDI.d489.s19.e5" origId="s19.p344" charOffset="201-218" type="drug" text="ethinyl estradiol"/><entity id="DrugDDI.d489.s19.e6" origId="s19.p349" charOffset="252-265" type="drug" text="norethindrone"/><pair id="DrugDDI.d489.s19.p0" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e1" interaction="false"/><pair id="DrugDDI.d489.s19.p1" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e2" interaction="false"/><pair id="DrugDDI.d489.s19.p2" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e3" interaction="false"/><pair id="DrugDDI.d489.s19.p3" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e4" interaction="false"/><pair id="DrugDDI.d489.s19.p4" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e5" interaction="false"/><pair id="DrugDDI.d489.s19.p5" e1="DrugDDI.d489.s19.e0" e2="DrugDDI.d489.s19.e6" interaction="false"/><pair id="DrugDDI.d489.s19.p6" e1="DrugDDI.d489.s19.e1" e2="DrugDDI.d489.s19.e2" interaction="true"/><pair id="DrugDDI.d489.s19.p7" e1="DrugDDI.d489.s19.e1" e2="DrugDDI.d489.s19.e3" interaction="false"/><pair id="DrugDDI.d489.s19.p8" e1="DrugDDI.d489.s19.e1" e2="DrugDDI.d489.s19.e4" interaction="false"/><pair id="DrugDDI.d489.s19.p9" e1="DrugDDI.d489.s19.e1" e2="DrugDDI.d489.s19.e5" interaction="false"/><pair id="DrugDDI.d489.s19.p10" e1="DrugDDI.d489.s19.e1" e2="DrugDDI.d489.s19.e6" interaction="false"/><pair id="DrugDDI.d489.s19.p11" e1="DrugDDI.d489.s19.e2" e2="DrugDDI.d489.s19.e3" interaction="false"/><pair id="DrugDDI.d489.s19.p12" e1="DrugDDI.d489.s19.e2" e2="DrugDDI.d489.s19.e4" interaction="false"/><pair id="DrugDDI.d489.s19.p13" e1="DrugDDI.d489.s19.e2" e2="DrugDDI.d489.s19.e5" interaction="false"/><pair id="DrugDDI.d489.s19.p14" e1="DrugDDI.d489.s19.e2" e2="DrugDDI.d489.s19.e6" interaction="false"/><pair id="DrugDDI.d489.s19.p15" e1="DrugDDI.d489.s19.e3" e2="DrugDDI.d489.s19.e4" interaction="false"/><pair id="DrugDDI.d489.s19.p16" e1="DrugDDI.d489.s19.e3" e2="DrugDDI.d489.s19.e5" interaction="false"/><pair id="DrugDDI.d489.s19.p17" e1="DrugDDI.d489.s19.e3" e2="DrugDDI.d489.s19.e6" interaction="false"/><pair id="DrugDDI.d489.s19.p18" e1="DrugDDI.d489.s19.e4" e2="DrugDDI.d489.s19.e5" interaction="false"/><pair id="DrugDDI.d489.s19.p19" e1="DrugDDI.d489.s19.e4" e2="DrugDDI.d489.s19.e6" interaction="false"/><pair id="DrugDDI.d489.s19.p20" e1="DrugDDI.d489.s19.e5" e2="DrugDDI.d489.s19.e6" interaction="false"/></sentence><sentence id="DrugDDI.d489.s20" origId="s20" text="therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced."><entity id="DrugDDI.d489.s20.e0" origId="s20.p354" charOffset="27-46" type="drug" text="oral contraceptives"/><entity id="DrugDDI.d489.s20.e1" origId="s20.p356" charOffset="72-82" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s20.p0" e1="DrugDDI.d489.s20.e0" e2="DrugDDI.d489.s20.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s21" origId="s21" text="Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used."><entity id="DrugDDI.d489.s21.e0" origId="s21.p362" charOffset="28-38" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s21.e1" origId="s21.p365" charOffset="64-83" type="drug" text="oral contraceptives"/><pair id="DrugDDI.d489.s21.p0" e1="DrugDDI.d489.s21.e0" e2="DrugDDI.d489.s21.e1" interaction="false"/></sentence><sentence id="DrugDDI.d489.s22" origId="s22" text="Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5."><entity id="DrugDDI.d489.s22.e0" origId="s22.p378" charOffset="0-9" type="drug" text="Midazolam"/><entity id="DrugDDI.d489.s22.e1" origId="s22.p380" charOffset="11-21" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s22.e2" origId="s22.p383" charOffset="43-52" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s22.e3" origId="s22.p384" charOffset="66-72" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s22.e4" origId="s22.p392" charOffset="155-164" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s22.e5" origId="s22.p399" charOffset="224-241" type="drug" text="Aprepitant 125 mg"/><pair id="DrugDDI.d489.s22.p0" e1="DrugDDI.d489.s22.e0" e2="DrugDDI.d489.s22.e1" interaction="false"/><pair id="DrugDDI.d489.s22.p1" e1="DrugDDI.d489.s22.e0" e2="DrugDDI.d489.s22.e2" interaction="false"/><pair id="DrugDDI.d489.s22.p2" e1="DrugDDI.d489.s22.e0" e2="DrugDDI.d489.s22.e3" interaction="false"/><pair id="DrugDDI.d489.s22.p3" e1="DrugDDI.d489.s22.e0" e2="DrugDDI.d489.s22.e4" interaction="false"/><pair id="DrugDDI.d489.s22.p4" e1="DrugDDI.d489.s22.e0" e2="DrugDDI.d489.s22.e5" interaction="false"/><pair id="DrugDDI.d489.s22.p5" e1="DrugDDI.d489.s22.e1" e2="DrugDDI.d489.s22.e2" interaction="true"/><pair id="DrugDDI.d489.s22.p6" e1="DrugDDI.d489.s22.e1" e2="DrugDDI.d489.s22.e3" interaction="false"/><pair id="DrugDDI.d489.s22.p7" e1="DrugDDI.d489.s22.e1" e2="DrugDDI.d489.s22.e4" interaction="false"/><pair id="DrugDDI.d489.s22.p8" e1="DrugDDI.d489.s22.e1" e2="DrugDDI.d489.s22.e5" interaction="false"/><pair id="DrugDDI.d489.s22.p9" e1="DrugDDI.d489.s22.e2" e2="DrugDDI.d489.s22.e3" interaction="false"/><pair id="DrugDDI.d489.s22.p10" e1="DrugDDI.d489.s22.e2" e2="DrugDDI.d489.s22.e4" interaction="false"/><pair id="DrugDDI.d489.s22.p11" e1="DrugDDI.d489.s22.e2" e2="DrugDDI.d489.s22.e5" interaction="false"/><pair id="DrugDDI.d489.s22.p12" e1="DrugDDI.d489.s22.e3" e2="DrugDDI.d489.s22.e4" interaction="false"/><pair id="DrugDDI.d489.s22.p13" e1="DrugDDI.d489.s22.e3" e2="DrugDDI.d489.s22.e5" interaction="false"/><pair id="DrugDDI.d489.s22.p14" e1="DrugDDI.d489.s22.e4" e2="DrugDDI.d489.s22.e5" interaction="false"/></sentence><sentence id="DrugDDI.d489.s23" origId="s23" text="The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant."><entity id="DrugDDI.d489.s23.e0" origId="s23.p408" charOffset="60-69" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s23.e1" origId="s23.p410" charOffset="79-94" type="drug" text="benzodiazepines"/><entity id="DrugDDI.d489.s23.e2" origId="s23.p412" charOffset="111-117" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s23.e3" origId="s23.p414" charOffset="119-129" type="drug" text="alprazolam"/><entity id="DrugDDI.d489.s23.e4" origId="s23.p415" charOffset="131-140" type="drug" text="triazolam"/><entity id="DrugDDI.d489.s23.e5" origId="s23.p423" charOffset="202-212" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s23.p0" e1="DrugDDI.d489.s23.e0" e2="DrugDDI.d489.s23.e1" interaction="false"/><pair id="DrugDDI.d489.s23.p1" e1="DrugDDI.d489.s23.e0" e2="DrugDDI.d489.s23.e2" interaction="false"/><pair id="DrugDDI.d489.s23.p2" e1="DrugDDI.d489.s23.e0" e2="DrugDDI.d489.s23.e3" interaction="false"/><pair id="DrugDDI.d489.s23.p3" e1="DrugDDI.d489.s23.e0" e2="DrugDDI.d489.s23.e4" interaction="false"/><pair id="DrugDDI.d489.s23.p4" e1="DrugDDI.d489.s23.e0" e2="DrugDDI.d489.s23.e5" interaction="true"/><pair id="DrugDDI.d489.s23.p5" e1="DrugDDI.d489.s23.e1" e2="DrugDDI.d489.s23.e2" interaction="false"/><pair id="DrugDDI.d489.s23.p6" e1="DrugDDI.d489.s23.e1" e2="DrugDDI.d489.s23.e3" interaction="false"/><pair id="DrugDDI.d489.s23.p7" e1="DrugDDI.d489.s23.e1" e2="DrugDDI.d489.s23.e4" interaction="false"/><pair id="DrugDDI.d489.s23.p8" e1="DrugDDI.d489.s23.e1" e2="DrugDDI.d489.s23.e5" interaction="false"/><pair id="DrugDDI.d489.s23.p9" e1="DrugDDI.d489.s23.e2" e2="DrugDDI.d489.s23.e3" interaction="false"/><pair id="DrugDDI.d489.s23.p10" e1="DrugDDI.d489.s23.e2" e2="DrugDDI.d489.s23.e4" interaction="false"/><pair id="DrugDDI.d489.s23.p11" e1="DrugDDI.d489.s23.e2" e2="DrugDDI.d489.s23.e5" interaction="false"/><pair id="DrugDDI.d489.s23.p12" e1="DrugDDI.d489.s23.e3" e2="DrugDDI.d489.s23.e4" interaction="false"/><pair id="DrugDDI.d489.s23.p13" e1="DrugDDI.d489.s23.e3" e2="DrugDDI.d489.s23.e5" interaction="true"/><pair id="DrugDDI.d489.s23.p14" e1="DrugDDI.d489.s23.e4" e2="DrugDDI.d489.s23.e5" interaction="false"/></sentence><sentence id="DrugDDI.d489.s24" origId="s24" text="In another study with intravenous administration of midazolam, Aprepitant was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and midazolam 2 mg IV was given prior to the administration of the 3-day regimen of Aprepitant and on Days 4, 8, and 15."><entity id="DrugDDI.d489.s24.e0" origId="s24.p426" charOffset="52-61" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s24.e1" origId="s24.p427" charOffset="63-73" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s24.e2" origId="s24.p439" charOffset="138-147" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s24.e3" origId="s24.p444" charOffset="218-228" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s24.p0" e1="DrugDDI.d489.s24.e0" e2="DrugDDI.d489.s24.e1" interaction="false"/><pair id="DrugDDI.d489.s24.p1" e1="DrugDDI.d489.s24.e0" e2="DrugDDI.d489.s24.e2" interaction="false"/><pair id="DrugDDI.d489.s24.p2" e1="DrugDDI.d489.s24.e0" e2="DrugDDI.d489.s24.e3" interaction="false"/><pair id="DrugDDI.d489.s24.p3" e1="DrugDDI.d489.s24.e1" e2="DrugDDI.d489.s24.e2" interaction="false"/><pair id="DrugDDI.d489.s24.p4" e1="DrugDDI.d489.s24.e1" e2="DrugDDI.d489.s24.e3" interaction="false"/><pair id="DrugDDI.d489.s24.p5" e1="DrugDDI.d489.s24.e2" e2="DrugDDI.d489.s24.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s25" origId="s25" text="Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3."><entity id="DrugDDI.d489.s25.e0" origId="s25.p450" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s25.e1" origId="s25.p453" charOffset="32-41" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s25.e2" origId="s25.p459" charOffset="83-92" type="drug" text="midazolam"/><entity id="DrugDDI.d489.s25.e3" origId="s25.p463" charOffset="135-145" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s25.p0" e1="DrugDDI.d489.s25.e0" e2="DrugDDI.d489.s25.e1" interaction="true"/><pair id="DrugDDI.d489.s25.p1" e1="DrugDDI.d489.s25.e0" e2="DrugDDI.d489.s25.e2" interaction="false"/><pair id="DrugDDI.d489.s25.p2" e1="DrugDDI.d489.s25.e0" e2="DrugDDI.d489.s25.e3" interaction="false"/><pair id="DrugDDI.d489.s25.p3" e1="DrugDDI.d489.s25.e1" e2="DrugDDI.d489.s25.e2" interaction="false"/><pair id="DrugDDI.d489.s25.p4" e1="DrugDDI.d489.s25.e1" e2="DrugDDI.d489.s25.e3" interaction="false"/><pair id="DrugDDI.d489.s25.p5" e1="DrugDDI.d489.s25.e2" e2="DrugDDI.d489.s25.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s26" origId="s26" text="These effects were not considered clinically important."/><sentence id="DrugDDI.d489.s27" origId="s27" text="The AUC of midazolam on Day 15 was similar to that observed at baseline."><entity id="DrugDDI.d489.s27.e0" origId="s27.p472" charOffset="11-20" type="drug" text="midazolam"/></sentence><sentence id="DrugDDI.d489.s28" origId="s28" text="Effect of other agents on the pharmacokinefics of aprepitant"><entity id="DrugDDI.d489.s28.e0" origId="s28.p482" charOffset="50-60" type="drug" text="aprepitant"/></sentence><sentence id="DrugDDI.d489.s29" origId="s29" text="Aprepitant is a substrate for CYP3A4;"><entity id="DrugDDI.d489.s29.e0" origId="s29.p483" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s29.e1" origId="s29.p486" charOffset="30-36" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s29.p0" e1="DrugDDI.d489.s29.e0" e2="DrugDDI.d489.s29.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s30" origId="s30" text="therefore, coadministration of Aprepitant with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of aprepitant."><entity id="DrugDDI.d489.s30.e0" origId="s30.p490" charOffset="31-41" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s30.e1" origId="s30.p491" charOffset="47-52" type="drug" text="drugs"/><entity id="DrugDDI.d489.s30.e2" origId="s30.p494" charOffset="66-72" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s30.e3" origId="s30.p498" charOffset="131-141" type="drug" text="aprepitant"/><pair id="DrugDDI.d489.s30.p0" e1="DrugDDI.d489.s30.e0" e2="DrugDDI.d489.s30.e1" interaction="true"/><pair id="DrugDDI.d489.s30.p1" e1="DrugDDI.d489.s30.e0" e2="DrugDDI.d489.s30.e2" interaction="false"/><pair id="DrugDDI.d489.s30.p2" e1="DrugDDI.d489.s30.e0" e2="DrugDDI.d489.s30.e3" interaction="false"/><pair id="DrugDDI.d489.s30.p3" e1="DrugDDI.d489.s30.e1" e2="DrugDDI.d489.s30.e2" interaction="false"/><pair id="DrugDDI.d489.s30.p4" e1="DrugDDI.d489.s30.e1" e2="DrugDDI.d489.s30.e3" interaction="false"/><pair id="DrugDDI.d489.s30.p5" e1="DrugDDI.d489.s30.e2" e2="DrugDDI.d489.s30.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s31" origId="s31" text="Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution."><entity id="DrugDDI.d489.s31.e0" origId="s31.p501" charOffset="44-54" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s31.e1" origId="s31.p502" charOffset="67-73" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s31.e2" origId="s31.p505" charOffset="92-104" type="drug" text="ketoconazole"/><entity id="DrugDDI.d489.s31.e3" origId="s31.p506" charOffset="106-118" type="drug" text="itraconazole"/><entity id="DrugDDI.d489.s31.e4" origId="s31.p507" charOffset="120-130" type="drug" text="nefazodone"/><entity id="DrugDDI.d489.s31.e5" origId="s31.p508" charOffset="132-146" type="drug" text="troleandomycin"/><entity id="DrugDDI.d489.s31.e6" origId="s31.p509" charOffset="148-162" type="drug" text="clarithromycin"/><entity id="DrugDDI.d489.s31.e7" origId="s31.p510" charOffset="164-173" type="drug" text="ritonavir"/><entity id="DrugDDI.d489.s31.e8" origId="s31.p511" charOffset="175-185" type="drug" text="nelfinavir"/><pair id="DrugDDI.d489.s31.p0" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e1" interaction="true"/><pair id="DrugDDI.d489.s31.p1" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e2" interaction="false"/><pair id="DrugDDI.d489.s31.p2" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e3" interaction="true"/><pair id="DrugDDI.d489.s31.p3" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e4" interaction="false"/><pair id="DrugDDI.d489.s31.p4" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e5" interaction="true"/><pair id="DrugDDI.d489.s31.p5" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p6" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e7" interaction="true"/><pair id="DrugDDI.d489.s31.p7" e1="DrugDDI.d489.s31.e0" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p8" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e2" interaction="false"/><pair id="DrugDDI.d489.s31.p9" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e3" interaction="false"/><pair id="DrugDDI.d489.s31.p10" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e4" interaction="false"/><pair id="DrugDDI.d489.s31.p11" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e5" interaction="false"/><pair id="DrugDDI.d489.s31.p12" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p13" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p14" e1="DrugDDI.d489.s31.e1" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p15" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e3" interaction="false"/><pair id="DrugDDI.d489.s31.p16" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e4" interaction="false"/><pair id="DrugDDI.d489.s31.p17" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e5" interaction="false"/><pair id="DrugDDI.d489.s31.p18" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p19" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p20" e1="DrugDDI.d489.s31.e2" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p21" e1="DrugDDI.d489.s31.e3" e2="DrugDDI.d489.s31.e4" interaction="false"/><pair id="DrugDDI.d489.s31.p22" e1="DrugDDI.d489.s31.e3" e2="DrugDDI.d489.s31.e5" interaction="false"/><pair id="DrugDDI.d489.s31.p23" e1="DrugDDI.d489.s31.e3" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p24" e1="DrugDDI.d489.s31.e3" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p25" e1="DrugDDI.d489.s31.e3" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p26" e1="DrugDDI.d489.s31.e4" e2="DrugDDI.d489.s31.e5" interaction="false"/><pair id="DrugDDI.d489.s31.p27" e1="DrugDDI.d489.s31.e4" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p28" e1="DrugDDI.d489.s31.e4" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p29" e1="DrugDDI.d489.s31.e4" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p30" e1="DrugDDI.d489.s31.e5" e2="DrugDDI.d489.s31.e6" interaction="false"/><pair id="DrugDDI.d489.s31.p31" e1="DrugDDI.d489.s31.e5" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p32" e1="DrugDDI.d489.s31.e5" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p33" e1="DrugDDI.d489.s31.e6" e2="DrugDDI.d489.s31.e7" interaction="false"/><pair id="DrugDDI.d489.s31.p34" e1="DrugDDI.d489.s31.e6" e2="DrugDDI.d489.s31.e8" interaction="false"/><pair id="DrugDDI.d489.s31.p35" e1="DrugDDI.d489.s31.e7" e2="DrugDDI.d489.s31.e8" interaction="false"/></sentence><sentence id="DrugDDI.d489.s32" origId="s32" text="Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution."><entity id="DrugDDI.d489.s32.e0" origId="s32.p517" charOffset="17-23" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s32.e1" origId="s32.p520" charOffset="42-51" type="drug" text="diltiazem"/><entity id="DrugDDI.d489.s32.e2" origId="s32.p525" charOffset="107-117" type="drug" text="aprepitant"/><pair id="DrugDDI.d489.s32.p0" e1="DrugDDI.d489.s32.e0" e2="DrugDDI.d489.s32.e1" interaction="false"/><pair id="DrugDDI.d489.s32.p1" e1="DrugDDI.d489.s32.e0" e2="DrugDDI.d489.s32.e2" interaction="true"/><pair id="DrugDDI.d489.s32.p2" e1="DrugDDI.d489.s32.e1" e2="DrugDDI.d489.s32.e2" interaction="false"/></sentence><sentence id="DrugDDI.d489.s33" origId="s33" text="Aprepitant is a substrate for CYP3A4;"><entity id="DrugDDI.d489.s33.e0" origId="s33.p532" charOffset="0-10" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s33.e1" origId="s33.p535" charOffset="30-36" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s33.p0" e1="DrugDDI.d489.s33.e0" e2="DrugDDI.d489.s33.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s34" origId="s34" text="therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant."><entity id="DrugDDI.d489.s34.e0" origId="s34.p539" charOffset="31-41" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s34.e1" origId="s34.p540" charOffset="47-52" type="drug" text="drugs"/><entity id="DrugDDI.d489.s34.e2" origId="s34.p543" charOffset="74-80" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s34.e3" origId="s34.p546" charOffset="97-105" type="drug" text="rifampin"/><entity id="DrugDDI.d489.s34.e4" origId="s34.p547" charOffset="107-120" type="drug" text="carbamazepine"/><entity id="DrugDDI.d489.s34.e5" origId="s34.p548" charOffset="122-131" type="drug" text="phenytoin"/><entity id="DrugDDI.d489.s34.e6" origId="s34.p553" charOffset="180-190" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s34.e7" origId="s34.p558" charOffset="232-242" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s34.p0" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e1" interaction="true"/><pair id="DrugDDI.d489.s34.p1" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e2" interaction="false"/><pair id="DrugDDI.d489.s34.p2" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e3" interaction="false"/><pair id="DrugDDI.d489.s34.p3" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e4" interaction="true"/><pair id="DrugDDI.d489.s34.p4" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e5" interaction="false"/><pair id="DrugDDI.d489.s34.p5" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p6" e1="DrugDDI.d489.s34.e0" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p7" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e2" interaction="false"/><pair id="DrugDDI.d489.s34.p8" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e3" interaction="false"/><pair id="DrugDDI.d489.s34.p9" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e4" interaction="false"/><pair id="DrugDDI.d489.s34.p10" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e5" interaction="false"/><pair id="DrugDDI.d489.s34.p11" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p12" e1="DrugDDI.d489.s34.e1" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p13" e1="DrugDDI.d489.s34.e2" e2="DrugDDI.d489.s34.e3" interaction="false"/><pair id="DrugDDI.d489.s34.p14" e1="DrugDDI.d489.s34.e2" e2="DrugDDI.d489.s34.e4" interaction="false"/><pair id="DrugDDI.d489.s34.p15" e1="DrugDDI.d489.s34.e2" e2="DrugDDI.d489.s34.e5" interaction="false"/><pair id="DrugDDI.d489.s34.p16" e1="DrugDDI.d489.s34.e2" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p17" e1="DrugDDI.d489.s34.e2" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p18" e1="DrugDDI.d489.s34.e3" e2="DrugDDI.d489.s34.e4" interaction="false"/><pair id="DrugDDI.d489.s34.p19" e1="DrugDDI.d489.s34.e3" e2="DrugDDI.d489.s34.e5" interaction="false"/><pair id="DrugDDI.d489.s34.p20" e1="DrugDDI.d489.s34.e3" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p21" e1="DrugDDI.d489.s34.e3" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p22" e1="DrugDDI.d489.s34.e4" e2="DrugDDI.d489.s34.e5" interaction="false"/><pair id="DrugDDI.d489.s34.p23" e1="DrugDDI.d489.s34.e4" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p24" e1="DrugDDI.d489.s34.e4" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p25" e1="DrugDDI.d489.s34.e5" e2="DrugDDI.d489.s34.e6" interaction="false"/><pair id="DrugDDI.d489.s34.p26" e1="DrugDDI.d489.s34.e5" e2="DrugDDI.d489.s34.e7" interaction="false"/><pair id="DrugDDI.d489.s34.p27" e1="DrugDDI.d489.s34.e6" e2="DrugDDI.d489.s34.e7" interaction="false"/></sentence><sentence id="DrugDDI.d489.s35" origId="s35" text="Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a"><entity id="DrugDDI.d489.s35.e0" origId="s35.p559" charOffset="0-12" type="drug" text="Ketoconazole"/><entity id="DrugDDI.d489.s35.e1" origId="s35.p563" charOffset="43-53" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s35.p0" e1="DrugDDI.d489.s35.e0" e2="DrugDDI.d489.s35.e1" interaction="false"/></sentence><sentence id="DrugDDI.d489.s36" origId="s36" text="10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold."><entity id="DrugDDI.d489.s36.e0" origId="s36.p571" charOffset="32-44" type="drug" text="ketoconazole"/><entity id="DrugDDI.d489.s36.e1" origId="s36.p572" charOffset="55-61" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s36.e2" origId="s36.p574" charOffset="84-94" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s36.e3" origId="s36.p579" charOffset="161-171" type="drug" text="aprepitant"/><pair id="DrugDDI.d489.s36.p0" e1="DrugDDI.d489.s36.e0" e2="DrugDDI.d489.s36.e1" interaction="false"/><pair id="DrugDDI.d489.s36.p1" e1="DrugDDI.d489.s36.e0" e2="DrugDDI.d489.s36.e2" interaction="true"/><pair id="DrugDDI.d489.s36.p2" e1="DrugDDI.d489.s36.e0" e2="DrugDDI.d489.s36.e3" interaction="false"/><pair id="DrugDDI.d489.s36.p3" e1="DrugDDI.d489.s36.e1" e2="DrugDDI.d489.s36.e2" interaction="false"/><pair id="DrugDDI.d489.s36.p4" e1="DrugDDI.d489.s36.e1" e2="DrugDDI.d489.s36.e3" interaction="false"/><pair id="DrugDDI.d489.s36.p5" e1="DrugDDI.d489.s36.e2" e2="DrugDDI.d489.s36.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s37" origId="s37" text="Concomitant administration of Aprepitant with strong CYP3A4 inhibitors should be approached cautiously."><entity id="DrugDDI.d489.s37.e0" origId="s37.p583" charOffset="30-40" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s37.e1" origId="s37.p584" charOffset="53-59" type="drug" text="CYP3A4"/><pair id="DrugDDI.d489.s37.p0" e1="DrugDDI.d489.s37.e0" e2="DrugDDI.d489.s37.e1" interaction="true"/></sentence><sentence id="DrugDDI.d489.s38" origId="s38" text="Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold."><entity id="DrugDDI.d489.s38.e0" origId="s38.p589" charOffset="0-8" type="drug" text="Rifampin"/><entity id="DrugDDI.d489.s38.e1" origId="s38.p593" charOffset="39-49" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s38.e2" origId="s38.p600" charOffset="112-120" type="drug" text="rifampin"/><entity id="DrugDDI.d489.s38.e3" origId="s38.p601" charOffset="131-137" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s38.e4" origId="s38.p603" charOffset="158-168" type="drug" text="aprepitant"/><pair id="DrugDDI.d489.s38.p0" e1="DrugDDI.d489.s38.e0" e2="DrugDDI.d489.s38.e1" interaction="false"/><pair id="DrugDDI.d489.s38.p1" e1="DrugDDI.d489.s38.e0" e2="DrugDDI.d489.s38.e2" interaction="false"/><pair id="DrugDDI.d489.s38.p2" e1="DrugDDI.d489.s38.e0" e2="DrugDDI.d489.s38.e3" interaction="false"/><pair id="DrugDDI.d489.s38.p3" e1="DrugDDI.d489.s38.e0" e2="DrugDDI.d489.s38.e4" interaction="false"/><pair id="DrugDDI.d489.s38.p4" e1="DrugDDI.d489.s38.e1" e2="DrugDDI.d489.s38.e2" interaction="true"/><pair id="DrugDDI.d489.s38.p5" e1="DrugDDI.d489.s38.e1" e2="DrugDDI.d489.s38.e3" interaction="false"/><pair id="DrugDDI.d489.s38.p6" e1="DrugDDI.d489.s38.e1" e2="DrugDDI.d489.s38.e4" interaction="false"/><pair id="DrugDDI.d489.s38.p7" e1="DrugDDI.d489.s38.e2" e2="DrugDDI.d489.s38.e3" interaction="false"/><pair id="DrugDDI.d489.s38.p8" e1="DrugDDI.d489.s38.e2" e2="DrugDDI.d489.s38.e4" interaction="false"/><pair id="DrugDDI.d489.s38.p9" e1="DrugDDI.d489.s38.e3" e2="DrugDDI.d489.s38.e4" interaction="false"/></sentence><sentence id="DrugDDI.d489.s39" origId="s39" text="Coadministration of Aprepitant with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of Aprepitant."><entity id="DrugDDI.d489.s39.e0" origId="s39.p611" charOffset="20-30" type="drug" text="Aprepitant"/><entity id="DrugDDI.d489.s39.e1" origId="s39.p612" charOffset="36-41" type="drug" text="drugs"/><entity id="DrugDDI.d489.s39.e2" origId="s39.p615" charOffset="54-60" type="drug" text="CYP3A4"/><entity id="DrugDDI.d489.s39.e3" origId="s39.p621" charOffset="140-150" type="drug" text="Aprepitant"/><pair id="DrugDDI.d489.s39.p0" e1="DrugDDI.d489.s39.e0" e2="DrugDDI.d489.s39.e1" interaction="true"/><pair id="DrugDDI.d489.s39.p1" e1="DrugDDI.d489.s39.e0" e2="DrugDDI.d489.s39.e2" interaction="false"/><pair id="DrugDDI.d489.s39.p2" e1="DrugDDI.d489.s39.e0" e2="DrugDDI.d489.s39.e3" interaction="false"/><pair id="DrugDDI.d489.s39.p3" e1="DrugDDI.d489.s39.e1" e2="DrugDDI.d489.s39.e2" interaction="false"/><pair id="DrugDDI.d489.s39.p4" e1="DrugDDI.d489.s39.e1" e2="DrugDDI.d489.s39.e3" interaction="false"/><pair id="DrugDDI.d489.s39.p5" e1="DrugDDI.d489.s39.e2" e2="DrugDDI.d489.s39.e3" interaction="false"/></sentence><sentence id="DrugDDI.d489.s40" origId="s40" text="Additional interactions"/><sentence id="DrugDDI.d489.s41" origId="s41" text="Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC."><entity id="DrugDDI.d489.s41.e0" origId="s41.p623" charOffset="0-9" type="drug" text="Diltiazem"/><entity id="DrugDDI.d489.s41.e1" origId="s41.p628" charOffset="77-87" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s41.e2" origId="s41.p635" charOffset="178-194" type="drug" text="diltiazem 120 mg"/><entity id="DrugDDI.d489.s41.e3" origId="s41.p639" charOffset="254-264" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s41.e4" origId="s41.p642" charOffset="309-318" type="drug" text="diltiazem"/><pair id="DrugDDI.d489.s41.p0" e1="DrugDDI.d489.s41.e0" e2="DrugDDI.d489.s41.e1" interaction="false"/><pair id="DrugDDI.d489.s41.p1" e1="DrugDDI.d489.s41.e0" e2="DrugDDI.d489.s41.e2" interaction="false"/><pair id="DrugDDI.d489.s41.p2" e1="DrugDDI.d489.s41.e0" e2="DrugDDI.d489.s41.e3" interaction="false"/><pair id="DrugDDI.d489.s41.p3" e1="DrugDDI.d489.s41.e0" e2="DrugDDI.d489.s41.e4" interaction="false"/><pair id="DrugDDI.d489.s41.p4" e1="DrugDDI.d489.s41.e1" e2="DrugDDI.d489.s41.e2" interaction="true"/><pair id="DrugDDI.d489.s41.p5" e1="DrugDDI.d489.s41.e1" e2="DrugDDI.d489.s41.e3" interaction="false"/><pair id="DrugDDI.d489.s41.p6" e1="DrugDDI.d489.s41.e1" e2="DrugDDI.d489.s41.e4" interaction="false"/><pair id="DrugDDI.d489.s41.p7" e1="DrugDDI.d489.s41.e2" e2="DrugDDI.d489.s41.e3" interaction="false"/><pair id="DrugDDI.d489.s41.p8" e1="DrugDDI.d489.s41.e2" e2="DrugDDI.d489.s41.e4" interaction="false"/><pair id="DrugDDI.d489.s41.p9" e1="DrugDDI.d489.s41.e3" e2="DrugDDI.d489.s41.e4" interaction="false"/></sentence><sentence id="DrugDDI.d489.s42" origId="s42" text="These pharmacokinetic effects did not result in clinically meaningful changes in ECG, heart rate or blood pressure beyond those changes induced by diltiazem alone."><entity id="DrugDDI.d489.s42.e0" origId="s42.p654" charOffset="147-156" type="drug" text="diltiazem"/></sentence><sentence id="DrugDDI.d489.s43" origId="s43" text="Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine."><entity id="DrugDDI.d489.s43.e0" origId="s43.p655" charOffset="0-10" type="drug" text="Paroxetine"/><entity id="DrugDDI.d489.s43.e1" origId="s43.p661" charOffset="52-62" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s43.e2" origId="s43.p668" charOffset="151-167" type="drug" text="paroxetine 20 mg"/><entity id="DrugDDI.d489.s43.e3" origId="s43.p680" charOffset="270-280" type="drug" text="aprepitant"/><entity id="DrugDDI.d489.s43.e4" origId="s43.p682" charOffset="285-295" type="drug" text="paroxetine"/><pair id="DrugDDI.d489.s43.p0" e1="DrugDDI.d489.s43.e0" e2="DrugDDI.d489.s43.e1" interaction="false"/><pair id="DrugDDI.d489.s43.p1" e1="DrugDDI.d489.s43.e0" e2="DrugDDI.d489.s43.e2" interaction="false"/><pair id="DrugDDI.d489.s43.p2" e1="DrugDDI.d489.s43.e0" e2="DrugDDI.d489.s43.e3" interaction="false"/><pair id="DrugDDI.d489.s43.p3" e1="DrugDDI.d489.s43.e0" e2="DrugDDI.d489.s43.e4" interaction="false"/><pair id="DrugDDI.d489.s43.p4" e1="DrugDDI.d489.s43.e1" e2="DrugDDI.d489.s43.e2" interaction="true"/><pair id="DrugDDI.d489.s43.p5" e1="DrugDDI.d489.s43.e1" e2="DrugDDI.d489.s43.e3" interaction="false"/><pair id="DrugDDI.d489.s43.p6" e1="DrugDDI.d489.s43.e1" e2="DrugDDI.d489.s43.e4" interaction="false"/><pair id="DrugDDI.d489.s43.p7" e1="DrugDDI.d489.s43.e2" e2="DrugDDI.d489.s43.e3" interaction="false"/><pair id="DrugDDI.d489.s43.p8" e1="DrugDDI.d489.s43.e2" e2="DrugDDI.d489.s43.e4" interaction="false"/><pair id="DrugDDI.d489.s43.p9" e1="DrugDDI.d489.s43.e3" e2="DrugDDI.d489.s43.e4" interaction="false"/></sentence></document>